The big investors are also buying the fear, pre-paying .87 a share for C warrants. This class of warrants was specifically designed for the 5-10% current holders. On6/30 retail traders were given the gift of buying 25-30% BELOW what the big boys paid. Christmas in June.
Frankly, I expected the offering price to be higher, but today's selloff is a combination of pure manipulation and quarter ending shenanigans. Today's price is an unfathomable giveaway-I wish I had more funds in which to average down.
kelvin: I've been thinking the same thing for the last six months. I expect ETRM to be above $1 by Friday as the dollars raised, including from Kevin Douglas, becomes known.
Kevin Douglas will almost certainly buy a few million C warrants, which he has to pay for up front. In fact he may have had a hand in designing this offering
Iwin: a stock offering with accompanying warrants is NOT a debt issue. I have never seen three classes of warrants before; this suggests some current large position holders in ETRM will be buyers of the new offering-a good sign.
People forget but the vast majority of Vbloc implants will be in the U.S. We have zero exposure to pauper markets like Greece where drug companies are owed billions of dollars, probably never to be collected .I'm tapped out, but there are ETRM bargains AH, and I urge new enacts to buy I the .80s(oops, it just jumped to .94)
This is no panic selling as nearly all micro and small cap companies are vulnerable to a programmed walk down. Buy now as I expect ETRM to issue some positive news in the near term.
I saw that article; however, it was only the ulcer patients who had their vagus nerve severed who had a reduced incidence of Parkinsons disease. Vbloc does not sever the vagus nerve.
crew: You need to offer a financial incentive for someone to call dozens of Vbloc clinics and spend hours emailing and telephoning surgeons. Your assignment: Call Dr Raul Rosenthal at Cleveland Clinic in Weston FL and ask why he was temporarily listed on the ETRM website, but then removed.
What amazes me is that there are zero buyout or partnership rumors regarding ETRM, while Medtronic does its third acquisition in two days and the markets are at record highs. BTW, I hate the peekaboo aspect of the surgeon locator: One day Cleveland Clinic shows up having a location in S Florida and then it disappears!
ETRM needs to discount/subsidize at least the first 1000 implants. The Market has rewarded many companies year after year with increasing sales, but skimpy or non-existent profits. Vbloc does not stand out based on superiority; however, it can stand out where price comes in. That is why we need a partner with the funds to grow Vbloc over the long term.
warren06: You chose to ignore the fact that this means that Medtronic has probably ceased being interested in engaging with Enteromedics and VBloc. Medtronic apparently thinks that it can make sleeve gastrectomy LESS INVASIVE and easier. The enormous weight loss with a sleeve gastrectomy vs. VBloc is a selling point with surgeons.
This is a real curve ball for Enteromedics and appears to remove Medtronic as a leading suitor. It's time for ETRM to announce that they have hired an investment banker to pursue all options. I fear that ETRM took a "let them come to us" position, which hasn't worked. Investment bankers typically send out at least 100 pitch books to every conceivable partner/buyer.
The most common weight-loss surgery is the sleeve gastrectomy, in which two-thirds of the stomach is removed to create a pouch that is roughly the size and shape of a banana without touching the intestines. Medtronic ($MDT) has come out with a surgical tool, the GastriSail gastric positioning system, that it says will enable surgeons to consistently size the pouch, as well as to decompress the pouch and test for leaks.
Previously, conducting these kinds of activities would have required surgeons to use three devices. The reduction of device insertions can limit the risks for irritations of and injuries to the esophagus during the procedure, according to a small cadaver study using the GastriSail system. FDA cleared the system in February.
"The GastriSail system is a first-of-its-kind in the bariatric industry, and demonstrates our continued commitment to fight obesity with specialized solutions that provide better patient outcomes and have the potential to increase adoption of this well-established procedure," said Chris Barry, SVP, president and president of the Surgical Innovations business that includes the Minimally Invasive Therapies Group at Medtronic, said in a statement.
Medtronic is launching GastriSail in the U.S., Europe and the Middle East, with global availability anticipated by year end. The device can be used to apply suction, for pouch decompression and as a sizing guide during bariatric procedures including the sleeve gastrectomy. It also includes LED lights to see a clear line showing where the stomach should be dissected, stapled and divided. The company said the tool enables more consistent sleeve creation and a more efficient surgical procedure than standard surgical pract
Connecticut still has a lot of generous medical plans that could py for VBLOC, not to mention pulling patients from New York state.
In a few days when Kevin Douglas does another SEC filing you will see that I am right. His latest filing put Enteromedics management on notice that he was taking a more active role.